Meyka Pro banner
Curaleaf Holdings, Inc.

Curaleaf Holdings, Inc. Fundamental Analysis (TSX: CURA.TO)

CURA.TOTSX
HealthcareDrug Manufacturers - Specialty & Generic
$13.47
$0.26(1.89%)
Canadian Market is Open · 14:33

Curaleaf Holdings, Inc. Fundamental Analysis (TSX: CURA.TO)

Curaleaf Holdings, Inc. (TSX: CURA.TO) shows weak financial fundamentals with a PE ratio of -65.19, profit margin of -2.82%, and ROE of -4.53%. The company generates $1.2B in annual revenue with weak year-over-year growth of 0.94%.

Key Strengths

PEG Ratio-0.61
Current Ratio1.52

Areas of Concern

ROE-4.53%
Operating Margin0.91%
Cash Position3.02%
We analyze CURA.TO's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 11.8/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
11.8/100

We analyze CURA.TO's fundamental strength across five key dimensions:

Efficiency Score

Weak

CURA.TO struggles to generate sufficient returns from assets.

ROA > 10%
-1.31%

Valuation Score

Excellent

CURA.TO trades at attractive valuation levels.

PE < 25
-65.19
PEG Ratio < 2
-0.61

Growth Score

Weak

CURA.TO faces weak or negative growth trends.

Revenue Growth > 5%
0.94%
EPS Growth > 10%
-6.90%

Financial Health Score

Moderate

CURA.TO shows balanced financial health with some risks.

Debt/Equity < 1
1.05
Current Ratio > 1
1.52

Profitability Score

Weak

CURA.TO struggles to sustain strong margins.

ROE > 15%
-453.42%
Net Margin ≥ 15%
-2.82%
Positive Free Cash Flow
Yes

Key Financial Metrics

Is CURA.TO Expensive or Cheap?

P/E Ratio

CURA.TO trades at -65.19 times earnings. This suggests potential undervaluation.

-65.19

PEG Ratio

When adjusting for growth, CURA.TO's PEG of -0.61 indicates potential undervaluation.

-0.61

Price to Book

The market values Curaleaf Holdings, Inc. at 2.97 times its book value. This may indicate undervaluation.

2.97

EV/EBITDA

Enterprise value stands at 8.90 times EBITDA. This is generally considered low.

8.90

How Well Does CURA.TO Make Money?

Net Profit Margin

For every $100 in sales, Curaleaf Holdings, Inc. keeps $-2.82 as profit after all expenses.

-2.82%

Operating Margin

Core operations generate 0.91 in profit for every $100 in revenue, before interest and taxes.

0.91%

ROE

Management delivers $-4.53 in profit for every $100 of shareholder equity.

-4.53%

ROA

Curaleaf Holdings, Inc. generates $-1.31 in profit for every $100 in assets, demonstrating efficient asset deployment.

-1.31%

Following the Money - Real Cash Generation

Operating Cash Flow

Curaleaf Holdings, Inc. produces operating cash flow of $125.11M, showing steady but balanced cash generation.

$125.11M

Free Cash Flow

Curaleaf Holdings, Inc. produces free cash flow of $67.36M, offering steady but limited capital for shareholder returns and expansion.

$67.36M

FCF Per Share

Each share generates $0.29 in free cash annually.

$0.29

FCF Yield

CURA.TO converts 3.37% of its market value into free cash.

3.37%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-65.19

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.61

vs 25 benchmark

P/B Ratio

Price to book value ratio

2.97

vs 25 benchmark

P/S Ratio

Price to sales ratio

1.74

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

1.05

vs 25 benchmark

Current Ratio

Current assets to current liabilities

1.52

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.05

vs 25 benchmark

ROA

Return on assets percentage

-0.01

vs 25 benchmark

ROCE

Return on capital employed

0.005

vs 25 benchmark

How CURA.TO Stacks Against Its Sector Peers

MetricCURA.TO ValueSector AveragePerformance
P/E Ratio-65.1932.02 Better (Cheaper)
ROE-4.53%569.00% Weak
Net Margin-2.82%29961.00% Weak
Debt/Equity1.050.53 Weak (High Leverage)
Current Ratio1.525.67 Neutral
ROA-1.31%-96.00% (disorted) Weak

CURA.TO outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Curaleaf Holdings, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

43.00%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

-185.64%

Industry Style: Defensive, Growth, Innovation

Declining

FCF CAGR

688.86%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ